Form 4: Coya Therapeutics Director Acquires Stock Options

Dieter Weinand, a director at Coya Therapeutics, acquired 5,000 stock options on January 1, 2025.

Summary

• Dieter Weinand, a director of Coya Therapeutics, acquired 5,000 stock options on January 1, 2025.
• The options have an exercise price of $5.73 per share.
• The options vest 100% on the first anniversary of the grant date, which is January 1, 2026.
• The options expire on January 1, 2035.
• The underlying security is common stock of Coya Therapeutics, with a par value of $0.0001 per share.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant, which is neither particularly positive nor negative. It is a standard practice for public companies.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of 100% after one year is a fairly standard vesting period for stock options.
• The exercise price of $5.73 is specific to Coya Therapeutics and would need to be compared to other similar companies to assess its relative value.

Stakeholder Impact

• The stock option grant could potentially align the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, insider trading, director, Coya Therapeutics, equity, options, beneficial ownership